Fractyl Health, Inc. ( (GUTS) ) just unveiled an update.
Fractyl Health, Inc., a metabolic therapeutics company, has unveiled promising preclinical data for its Rejuva RJVA-001, a single-administration GLP-1 pancreatic gene therapy, showcasing sustained weight maintenance in mice. Alongside, the firm nominated RJVA-002 as its first GIP/GLP-1 gene therapy candidate targeting obesity, aiming to transform metabolic disease treatment by addressing root causes. These developments highlight Fractyl’s innovative approach to tackling obesity and Type 2 Diabetes, offering potential long-term solutions without chronic therapies.
For detailed information about GUTS stock, go to TipRanks’ Stock Analysis page.
